Join the AgeneBio team at these upcoming industry events.

July 16, 2017

Alzheimer’s Association International Conference (AAIC)

Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.” Click title link for details.

September 13, 2016

17th International Conference on Alzheimer’s Drug Discovery

Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation. During the conference, Dr. Rosenzweig-Lipson was interviewed by NJTV News.

February 23, 2016

Neuroscience BioPartnering & Investment Forum

CEO Jerry McLaughlin will present at the Neuroscience BioPartnering & Investment Forum on Tuesday, February 23, at 3:35 pm Eastern Time. The BIO CEO & Investor Conference is being held at The New York Academy of Sciences.

February 2, 2016

BIO CEO & Investor Conference

CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at 10:15 am Eastern Time. The BIO CEO & Investor Conference is being held February 8 and 9 at the Waldorf Astoria New York.

November 7, 2015

Clinical Trials on Alzheimer’s Disease (CTAD)

Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI AgeneBio’s Michela Gallagher and Sharon Rosenzweig-Lipson to present in Barcelona on Saturday, November 7, 2015, at 11:45 am

October 6, 2015

BIO Investor Forum

October 20-21, 2015, San Francisco, CA. CEO Jerry McLaughlin will speak on Wednesday, October 21, at 9 am Pacific time.

September 30, 2015

USAgainstAlzheimer’s Summit

AgeneBio’s Michela Gallagher spoke on the impact and role of NIH funding on advances in science and clinical trials targeting the prevention of Alzheimer’s disease on Wednesday, September 30, 2015,  in Washington, DC.